New targets for off-the-shelf treatments open up the field of precision immunotherapy
The identification of mutation-derived neoantigens may help elicit antitumour immune responses in patients with cancer, but this approach is challenging
Cancer Control Principles
You are not your COI, but COI can make you
There is a misunderstanding in what financial conflict of interests do on single people and what system implications they may have
Cancer Research
Artificial Intelligence: a ‘smart’ arrow in our quiver against cancer
Many studies presented at ESMO Congress 2022 show the potential of artificial intelligence to enhance personalised oncology
First-line triplet of TKI plus dual immunotherapy improves outcomes in renal cell carcinoma
Results from the COSMIC-313 trial show that adding cabozantinib to nivolumab plus ipilimumab prolongs progression-free survival, but also increases toxicity
Prostate cancer: data support adding ADT for patients undergoing post-operative radiotherapy
Results from the RADICALS-HD and PRESTO trials show encouraging metastasis-free and biochemical progression-free survival benefits with androgen deprivation therapy, but they are not practice-changing yet
Sotorasib improves PFS versus docetaxel in patients with pre-treated KRAS G12C-mutated NSCLC
Results from the CodeBreaK 200 trial represent an improvement for a difficult-to-treat patient population
Could anti-PD-L1 be the best choice as front-line therapy in platinum-ineligible patients with NSCLC?
Findings show overall survival benefits with front-line atezolizumab versus single-agent chemotherapy, but questions remain regarding who might benefit
The first randomised study of peptide receptor radionuclide therapy in pancreatic NETs met its primary endpoint
In the OCLURANDOM trial, progression-free survival was longer in patients receiving lutetium-octreotate versus sunitinib
NECs: mixed results for second-line therapy after progression
The optimal chemotherapy regimen in this setting is not well-defined
Antibody–drug conjugates show potential in advanced solid tumours
Study data report promising responses and safety profiles in patients with heavily pre-treated malignancies